Phase II Trial of VistusertibAZD2014 Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Vistusertib (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- 17 May 2019 Planned End Date changed from 1 Dec 2019 to 31 Jul 2018.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2018 to 31 Jul 2018.
- 17 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.